PF-07304814 | 2468015-78-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: PF-07304814
• 英文别名: (S)-3-((S)-2-(4-methoxy-1H-indole-2-carboxamido)-4-methylpentanamido)-2-oxo-4-((S)-2-oxopyrrolidin-3-yl)butyl dihydrogen phosphate；Lufotrelvir；[(3S)-3-[[(2S)-2-[(4-methoxy-1H-indole-2-carbonyl)amino]-4-methylpentanoyl]amino]-2-oxo-4-[(3S)-2-oxopyrrolidin-3-yl]butyl] dihydrogen phosphate
• CAS: 2468015-78-1
• 化学式: C₂₄H₃₃N₄O₉P
• 分子量: 552.521
• InChiKey: FQKALOFOWPDTED-WBAXXEDZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  38
• 可旋转键数：
  13
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  196
• 氢给体数：
  6
• 氢受体数：
  9

文献信息

• Compounds and Methods for the Treatment of COVID-19
  申请人：Pfizer Inc.

  公开号：US20220017548A1

  公开（公告）日：2022-01-20

  The invention relates to compounds of formula I wherein R 1 , R 2 and - - - - - are as defined herein, pharmaceutical compositions comprising the compounds and methods of treating COVID-19 in a patient by administering therapeutically effective amounts of the compounds and methods of inhibiting or preventing replication of SARS-CoV-2 with the compounds.
• [EN] DRUGS, THERAPEUTIC COMBINATIONS AND METHODS FOR PREVENTING VIRAL AND MICROBIAL INFECTIONS AND THEIR SEQUELAE<br/>[FR] MÉDICAMENTS, COMBINAISONS THÉRAPEUTIQUES ET MÉTHODES POUR PRÉVENIR DES INFECTIONS VIRALES ET MICROBIENNES ET LEURS SÉQUELLES
  申请人：[en]TOPELIA AUST LIMITED (ACN 652 771 670)

  公开号：WO2022126207A1

  公开（公告）日：2022-06-23

  Therapeutic agents, combination therapies, and methods for the treatment of coronavirus infections and associated diseases, particularly COVID-19, are provided. The provided therapeutics include ivermectin (at doses of 0.3 mg/kg or higher), doxycycline, zinc, azithromycin, hydroxychloroquine, fenofibrate, vitamin D, nirmatrelvir, ritonavir, or ribavirin and combinations thereof.